QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS
Amy Puenpatom 1
Ping Xu 2
Anjela Tzontcheva 2
Tony Terzis 3
Alan Meehan 4
Cindy L J Weinstein 2
1 Merck & Co., Inc.,Upper Gwynedd,United States
2 Merck & Co., Inc.,Rahway,United States
3 MSD Switzerland,Kriens,Switzerland
4 Merck & Co., Inc.,Kenilworth,United States
Session
IBD (Posters)
Conference
UEG Week Virtual 2020
Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing